JP2017525737A5 - - Google Patents

Download PDF

Info

Publication number
JP2017525737A5
JP2017525737A5 JP2017512046A JP2017512046A JP2017525737A5 JP 2017525737 A5 JP2017525737 A5 JP 2017525737A5 JP 2017512046 A JP2017512046 A JP 2017512046A JP 2017512046 A JP2017512046 A JP 2017512046A JP 2017525737 A5 JP2017525737 A5 JP 2017525737A5
Authority
JP
Japan
Prior art keywords
group
alkyl
substituted
cycloalkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017512046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525737A (ja
JP6506390B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2015/088799 external-priority patent/WO2016034108A1/zh
Publication of JP2017525737A publication Critical patent/JP2017525737A/ja
Publication of JP2017525737A5 publication Critical patent/JP2017525737A5/ja
Application granted granted Critical
Publication of JP6506390B2 publication Critical patent/JP6506390B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017512046A 2014-09-02 2015-09-01 キノリノン系化合物及びその薬物への使用 Active JP6506390B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410442574.4 2014-09-02
CN201410442574 2014-09-02
PCT/CN2015/088799 WO2016034108A1 (zh) 2014-09-02 2015-09-01 喹啉酮类化合物及其应用

Publications (3)

Publication Number Publication Date
JP2017525737A JP2017525737A (ja) 2017-09-07
JP2017525737A5 true JP2017525737A5 (enExample) 2018-06-14
JP6506390B2 JP6506390B2 (ja) 2019-04-24

Family

ID=55417512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512046A Active JP6506390B2 (ja) 2014-09-02 2015-09-01 キノリノン系化合物及びその薬物への使用

Country Status (8)

Country Link
US (1) US10065928B2 (enExample)
EP (1) EP3190104B1 (enExample)
JP (1) JP6506390B2 (enExample)
CN (1) CN105384687B (enExample)
AU (1) AU2015311333B2 (enExample)
CA (1) CA2959688C (enExample)
ES (1) ES2898476T3 (enExample)
WO (1) WO2016034108A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106146414A (zh) * 2016-07-07 2016-11-23 浙江大学 喹唑啉二酮类衍生物及其制备方法和用途
CN108069952B (zh) * 2016-11-08 2022-09-27 广东东阳光药业有限公司 喹啉酮类化合物及其在药物中应用
CN108069957B (zh) * 2016-11-09 2022-11-04 广东东阳光药业有限公司 脯氨酰羟化酶抑制剂及其用途
CN108285460A (zh) * 2017-01-09 2018-07-17 南京圣和药业股份有限公司 一种egfr激酶抑制剂的药用盐及其制备方法与用途
JP6999469B2 (ja) * 2018-03-28 2022-01-18 東京応化工業株式会社 水素バリア剤、水素バリア膜形成用組成物、水素バリア膜、水素バリア膜の製造方法、及び電子素子
JP7680447B2 (ja) * 2019-11-28 2025-05-20 サンシャイン・レイク・ファーマ・カンパニー・リミテッド キノリノン系化合物の結晶形及びその用途
CN111269178A (zh) * 2019-11-28 2020-06-12 南北兄弟药业投资有限公司 喹啉酮类化合物的晶型
CN111269176A (zh) * 2019-11-28 2020-06-12 南北兄弟药业投资有限公司 喹啉酮类化合物的晶型
CN111269177B (zh) * 2019-11-28 2023-05-09 广东东阳光药业有限公司 喹啉酮类化合物的晶型
CN115010663A (zh) * 2021-03-05 2022-09-06 广东东阳光药业有限公司 喹啉酮类化合物的晶型及其用途
CN115010664A (zh) * 2021-03-05 2022-09-06 广东东阳光药业有限公司 喹啉酮类化合物的晶型及其用途
WO2022184159A1 (zh) * 2021-03-05 2022-09-09 广东东阳光药业有限公司 喹啉酮类化合物的晶型及其用途
CN114989085B (zh) * 2022-05-23 2023-11-24 安徽医科大学 一种芳基内酰胺环类化合物、药物组合物及其应用
CN117159549B (zh) * 2023-10-11 2025-02-14 中国药科大学 一种酯类化合物的应用
WO2026021503A1 (zh) * 2024-07-24 2026-01-29 合肥医工医药股份有限公司 喹啉衍生物及其制备方法和用途

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103145616B (zh) 2003-06-06 2015-09-30 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
EP1849465A4 (en) * 2005-02-18 2008-12-24 Takeda Pharmaceutical AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR
US8703795B2 (en) 2005-03-02 2014-04-22 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
AU2006326662B2 (en) * 2005-12-09 2011-07-28 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
CN102351791B (zh) 2006-01-27 2014-10-29 菲布罗根有限公司 使低氧诱导因子(hif)稳定的氰基异喹啉化合物
PE20071020A1 (es) * 2006-03-07 2007-12-11 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa
AU2007234408B2 (en) 2006-04-04 2011-05-19 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as HIF modulators
JP2009537558A (ja) 2006-05-16 2009-10-29 スミスクライン・ビーチャム・コーポレイション プロリルヒドロキシラーゼ阻害剤
TWI394747B (zh) 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
NZ623002A (en) 2006-06-26 2015-08-28 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
US8048892B2 (en) 2006-12-18 2011-11-01 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
WO2008076427A2 (en) 2006-12-18 2008-06-26 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
CL2008000066A1 (es) 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
ES2446418T3 (es) 2007-04-18 2014-03-07 Amgen, Inc Derivados de indanona que inhiben la prolil hidroxilasa
WO2008130527A1 (en) 2007-04-18 2008-10-30 Merck & Co., Inc. Novel 1,8-naphthyridine compounds
EP2142509B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Quinolones and azaquinolones that inhibit prolyl hydroxylase
US8030346B2 (en) 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
US20110028507A1 (en) 2007-08-10 2011-02-03 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
WO2009039322A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JP2011505367A (ja) 2007-11-30 2011-02-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
WO2009073497A2 (en) 2007-11-30 2009-06-11 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
EP2240178A4 (en) 2007-12-19 2011-10-26 Glaxosmithkline Llc PROLYLHYDROXYLASEHEMMER
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
CN101951776A (zh) 2008-02-25 2011-01-19 默沙东公司 四氢-1h-吡咯稠合吡啶酮
CN101951775A (zh) 2008-02-25 2011-01-19 默沙东公司 四氢噻吩并吡啶
CA2716798A1 (en) 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydrofuropyridones
PT2294066E (pt) 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
WO2009134847A1 (en) 2008-04-30 2009-11-05 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009134850A1 (en) 2008-04-30 2009-11-05 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
US20110098324A1 (en) 2008-06-25 2011-04-28 Brackley Iii James A Prolyl hydroxylase inhibitors
CN102264740B (zh) 2008-08-20 2014-10-15 菲布罗根有限公司 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途
WO2010022307A2 (en) 2008-08-21 2010-02-25 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2010025087A1 (en) 2008-08-25 2010-03-04 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
JP5643233B2 (ja) 2009-02-10 2014-12-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap プロリルヒドロキシラーゼ阻害物質としてのキナゾリノン
IN2012DN00549A (enExample) 2009-07-15 2015-06-12 Zhejiang Beta Pharma Inc
US8283465B2 (en) 2009-07-17 2012-10-09 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
WO2011048611A1 (en) 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives
TWI500623B (zh) 2009-10-13 2015-09-21 Torrent Pharmaceuticals Ltd 新穎稠合噻唑及噁唑嘧啶酮
WO2011056725A1 (en) 2009-11-05 2011-05-12 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
US8541430B2 (en) 2009-11-27 2013-09-24 Torrent Pharmaceuticals Limited Fused thiazolo and oxazolo pyrimidinones
EP2603502B1 (en) 2010-08-13 2014-07-30 Janssen Pharmaceutica, N.V. 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors
EP2670750B1 (en) 2011-02-02 2016-09-14 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor
NO2686520T3 (enExample) 2011-06-06 2018-03-17
CN103717214A (zh) 2011-06-06 2014-04-09 阿克比治疗有限公司 用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物
EP2736892A4 (en) 2011-07-29 2015-03-18 Beijing Betta Pharmaceuticals Co Ltd STABLE POLYMORPHIC FORMS OF A CONNECTION AS HYPOXIEMIMETICS AND USES THEREOF
WO2013134660A1 (en) 2012-03-09 2013-09-12 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
SG11201500234YA (en) 2012-07-16 2015-02-27 Fibrogen Inc Process for making isoquinoline compounds
KR102018409B1 (ko) 2012-07-30 2019-09-04 다이쇼 세이야꾸 가부시끼가이샤 부분적으로 포화된 질소 함유 복소환 화합물
JPWO2014030716A1 (ja) 2012-08-23 2016-08-08 田辺三菱製薬株式会社 ピラゾロピリミジン化合物
AP2015008502A0 (en) * 2012-12-24 2015-06-30 Cadila Healthcare Ltd Novel quinolone derivatives
SG10202009266PA (en) 2013-01-24 2020-10-29 Fibrogen Inc Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid

Similar Documents

Publication Publication Date Title
JP2014511891A5 (enExample)
JP2019524883A5 (enExample)
JP2017523225A5 (enExample)
JP2010532387A5 (enExample)
JP2018537413A5 (ja) 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物
JP2017527561A5 (enExample)
JP2017531619A5 (enExample)
JP2015522650A5 (enExample)
JP2016540742A5 (enExample)
JP2015537020A5 (enExample)
JP2018514544A5 (enExample)
JP2014507455A5 (enExample)
JP2016505512A5 (enExample)
AR092045A1 (es) Combinaciones farmaceuticas
JP2019510034A5 (enExample)
JP2015524472A5 (enExample)
JP2015504081A5 (enExample)
JP2016531126A5 (enExample)
JP2013542261A5 (enExample)
JP2016507581A5 (enExample)
RU2012158142A (ru) Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
RU2015146957A (ru) Производные доластатина 10 и ауристатинов
JP2019531279A5 (enExample)
JP2014513051A5 (enExample)
JP2017516796A5 (enExample)